Brief: Medicenna Therapeutics Completes MDNA11 Dose Escalation And Commences Monotherapy Dose Expansion In Phase 1/2 Ability Study
09/08/2023 13:27
Aug 9 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA COMPLETES MDNA11 DOSE ESCALATION AND COMMENCES
MONOTHERAPY DOSE EXPANSION IN THE PHASE 1/2 ABILITY STUDY
Source text for Eikon: ID:nGNX2C4m7f
Further company coverage: MDNA.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results